MET and MYC cooperate in mammary tumorigenesis
Authors:
Open Access
- 28 February 2005
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 102 (12) , 4324-4329
Abstract
In human breast cancer, overexpression of the protooncogene MET is strongly associated with poor prognosis and high risk of metastasis. It stands out as a reliable prognostic indicator of survival and defines a set of tumors exclusive of those that express HER2 or hormone receptors. Studies have shown that overexpression of mutant forms of MET cause cancer in mice. However, MET mutations have not been found in human breast cancer, and the consequences of overexpression of normal MET are unknown. To investigate the role of MET and other putative oncogenes in breast cancer, we developed an experimental system that involves retroviral delivery of genes into primary mammary epithelial cells, followed by transplantation of the transduced cells into mammary fat pads. Using this approach, we found that overexpression of wild-type MET leads to the development of nonprogressive neoplasms. The lesions progressed to mammary adenocarcinoma when a second protooncogene, MYC , was overexpressed, indicating that MET and MYC cooperate in mammary tumorigenesis. Both the nonprogressive neoplasms and adenocarcinomas display characteristics consistent with transformation and expansion of mammary progenitor cells. The approach described here should provide a useful model with which to efficiently test effects of various genes on tumor development in the breast.Keywords
This publication has 38 references indexed in Scilit:
- Breast cancer, stem/progenitor cells and the estrogen receptorTrends in Endocrinology & Metabolism, 2004
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003
- Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathwaysOncogene, 2003
- Stem cells in normal breast development and breast cancerCell Proliferation, 2003
- Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptorsCancer, 2003
- A novel doxycycline‐inducible system for the transgenic analysis of mammary gland biologyThe FASEB Journal, 2002
- c-Myc in breast cancer.Endocrine-Related Cancer, 2000
- Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors.Journal of Clinical Investigation, 1996
- Steroid hormone receptor status defines the MMTV promoter chromatin structure in vivoThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genesCell, 1984